Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Sep;41(9):1961–1964. doi: 10.1128/aac.41.9.1961

Effect of foscarnet cream on experimental UV radiation-induced herpes labialis.

D I Bernstein 1, C J Schleupner 1, T G Evans 1, D A Blumberg 1, Y Bryson 1, K Grafford 1, P Broberg 1, S Martin-Munley 1, S L Spruance 1
PMCID: PMC164045  PMID: 9303394

Abstract

A topical 3% foscarnet cream formulation was evaluated for its ability to treat experimental UV radiation (UVR)-induced herpes labialis in a double-blind study. Healthy adult volunteers with a history of sunlight-induced herpes labialis were randomly assigned at four centers to receive either foscarnet cream (n = 152) or a vehicle control (n = 150). Following measurement of the minimal erythematous dose (MED), the subjects' lips were exposed to 4 MEDs of UV light. Subjects applied the cream on the UVR-exposed area approximately eight times daily beginning immediately after UVR exposure and continuing for 7 days, or until all lesions had a minimum of 4 days of treatment. There were no significant differences between groups in the percentages of subjects that developed any lesion, aborted lesions (did not progress beyond a papule), immediate lesions (developed within 48 h of UVR), or delayed classic lesions (developed 48 h to 7 days after UVR). Treatment with foscarnet significantly reduced the mean lesion area (49 versus 81 mm2; P = 0.01), the maximum lesion area (80 versus 141 mm2; P = 0.01), and the time to healing (P = 0.03) of the delayed classic lesions (n = 78). There was also a trend for a decrease in the mean duration of these lesions (156 versus 191 h; P = 0.08) and the duration of pain (3.9 versus 4.3 days; P = 0.06) in foscarnet-treated subjects. There were no clinically significant adverse reactions. These data suggest that topical foscarnet can be efficacious and deserves further evaluation for the treatment of herpes labialis.

Full Text

The Full Text of this article is available as a PDF (180.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alenius S., Berg M., Broberg F., Eklind K., Lindborg B., Oberg B. Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs. J Infect Dis. 1982 Apr;145(4):569–573. doi: 10.1093/infdis/145.4.569. [DOI] [PubMed] [Google Scholar]
  2. Balfour H. H., Jr, Benson C., Braun J., Cassens B., Erice A., Friedman-Kien A., Klein T., Polsky B., Safrin S. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr. 1994 Mar;7(3):254–260. [PubMed] [Google Scholar]
  3. Balfour H. H., Jr Management of cytomegalovirus disease with antiviral drugs. Rev Infect Dis. 1990 Sep-Oct;12 (Suppl 7):S849–S860. doi: 10.1093/clinids/12.supplement_7.s849. [DOI] [PubMed] [Google Scholar]
  4. Barton S. E., Munday P. E., Kinghorn G. R., van der Meijden W. I., Stolz E., Notowicz A., Rashid S., Schuller J. L., Essex-Cater A. J., Kuijpers M. H. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. Genitourin Med. 1986 Aug;62(4):247–250. doi: 10.1136/sti.62.4.247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bernstein D. I., Rheins L. A. Solar simulator-induced herpes simplex labialis: use in evaluating treatment with acyclovir plus 348U87. Antiviral Res. 1994 Apr;23(3-4):225–233. doi: 10.1016/0166-3542(94)90020-5. [DOI] [PubMed] [Google Scholar]
  6. Clements G. B., Subak-Sharpe J. H. Herpes simplex virus type 2 establishes latency in the mouse footpad. J Gen Virol. 1988 Feb;69(Pt 2):375–383. doi: 10.1099/0022-1317-69-2-375. [DOI] [PubMed] [Google Scholar]
  7. Fiddian A. P., Yeo J. M., Stubbings R., Dean D. Successful treatment of herpes labialis with topical acyclovir. Br Med J (Clin Res Ed) 1983 May 28;286(6379):1699–1701. doi: 10.1136/bmj.286.6379.1699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hill T. J., Harbour D. A., Blyth W. A. Isolation of herpes simplex virus from the skin of clinically normal mice during latent infection. J Gen Virol. 1980 Mar;47(1):205–207. doi: 10.1099/0022-1317-47-1-205. [DOI] [PubMed] [Google Scholar]
  9. Lawee D., Rosenthal D., Aoki F. Y., Portnoy J. Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study. CMAJ. 1988 Feb 15;138(4):329–333. [PMC free article] [PubMed] [Google Scholar]
  10. Lim K. B., Doraisingham S., Thirumoorthy T., Lee C. T., Ling A. E., Tan T. Foscarnet (phosphonoformate sodium) in the treatment of recurrent male genital herpes. Ann Acad Med Singapore. 1986 Oct;15(4):617–622. [PubMed] [Google Scholar]
  11. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther. 1982;19(3):387–415. doi: 10.1016/0163-7258(82)90074-2. [DOI] [PubMed] [Google Scholar]
  12. Openshaw H., McNeill J. I., Lin X. H., Niland J., Cantin E. M. Herpes simplex virus DNA in normal corneas: persistence without viral shedding from ganglia. J Med Virol. 1995 May;46(1):75–80. doi: 10.1002/jmv.1890460116. [DOI] [PubMed] [Google Scholar]
  13. Raborn G. W., McGaw W. T., Grace M., Percy J., Samuels S. Herpes labialis treatment with acyclovir 5% modified aqueous cream: a double-blind randomized trial. Oral Surg Oral Med Oral Pathol. 1989 Jun;67(6):676–679. doi: 10.1016/0030-4220(89)90007-8. [DOI] [PubMed] [Google Scholar]
  14. Raborn G. W., McGaw W. T., Grace M., Tyrrell L. D., Samuels S. M. Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study. J Am Dent Assoc. 1987 Jul;115(1):38–42. doi: 10.14219/jada.archive.1987.0211. [DOI] [PubMed] [Google Scholar]
  15. Shaw M., King M., Best J. M., Banatvala J. E., Gibson J. R., Klaber M. R. Failure of acyclovir cream in treatment of recurrent herpes labialis. Br Med J (Clin Res Ed) 1985 Jul 6;291(6487):7–9. doi: 10.1136/bmj.291.6487.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Spruance S. L., Freeman D. J., Stewart J. C., McKeough M. B., Wenerstrom L. G., Krueger G. G., Piepkorn M. W., Stroop W. G., Rowe N. H. The natural history of ultraviolet radiation-induced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir. J Infect Dis. 1991 Apr;163(4):728–734. doi: 10.1093/infdis/163.4.728. [DOI] [PubMed] [Google Scholar]
  17. Spruance S. L. Pathogenesis of herpes simplex labialis: experimental induction of lesions with UV light. J Clin Microbiol. 1985 Sep;22(3):366–368. doi: 10.1128/jcm.22.3.366-368.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Spruance S. L. Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis. J Med Virol. 1993;Suppl 1:27–32. doi: 10.1002/jmv.1890410507. [DOI] [PubMed] [Google Scholar]
  19. Van Vloten W. A., Swart R. N., Pot F. Topical acyclovir therapy in patients with recurrent orofacial herpes simplex infections. J Antimicrob Chemother. 1983 Sep;12 (Suppl B):89–93. doi: 10.1093/jac/12.suppl_b.89. [DOI] [PubMed] [Google Scholar]
  20. Wallin J., Lernestedt J. O., Ogenstad S., Lycke E. Topical treatment of recurrent genital herpes infections with foscarnet. Scand J Infect Dis. 1985;17(2):165–172. doi: 10.3109/inf.1985.17.issue-2.07. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES